Novo Nordisk shares plunge 22% after CagriSema obesity drug trial results

Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy.Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 24% on Friday, putting it on course for its worst-ever daily loss, after reporting results in a late-stage trial for its experimental CagriSema weight loss drug that missed expectations.The maker of the wildly popular Wegovy obesity drug said its new drug candidate helped patients reduce their weight by 22.7%, below the 25% it had forecast, according to Reuters.The s ...